In a recent study, scientists from Stanford University and collaborators aimed to develop a platform for specific tumor-immune cell targeting, focusing on tumor-associated macrophages (TAMs), with the eventual goal of interfacing with existing immune checkpoint inhibitor technologies.

SL Science Holding Ltd. has submitted an orphan drug designation request to the FDA for its γδ T-cell therapy product, Vδ2+ γδ T cells, for the treatment of glioblastoma multiforme.

Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions.

Rybodyn Inc. has been awarded $1.3 million from the U.S. Department of War to advance preclinical development of two novel antibody-based therapies for lung cancer.

Urogen Pharma Ltd. has obtained IND approval from the FDA for UGN-501, a next-generation investigational oncolytic virus. A phase I study evaluating intravesical administration of UGN-501 in patients with non-muscle invasive bladder cancer (NMIBC) is expected to begin in the fourth quarter.

Researchers from Hainan Medical University and collaborators have demonstrated that PGE2-EP2/EP4-G α s-PKA signaling drove the expansion of immunosuppressive VSIG4-high macrophages and promoted immunotherapy resistance in colorectal cancer (CRC).

Coregen Inc. has obtained IND clearance from the FDA for CRG-150, a novel adoptive cell therapy targeting SRC-3 (steroid receptor coactivator 3).

LTZ Therapeutics Inc.’s LTZ-232 has gained IND clearance from the FDA, enabling initiation of a phase I study in patients with advanced metastatic colorectal cancer and other solid tumors.

Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions.